PrIMAVeRa: new publication – Systematic review of existing AMR transmission models
- europevaccine
- 14 hours ago
- 1 min read
June 2025
PrIMAVeRa partners celebrate the newest project manuscript to be published, titled The neglected model validation of antimicrobial resistance transmission models – a systematic review.
Not only are previously identified modelling gaps explored in the review, but the scope is also expanded to include monoclonal antibodies as a control measure and investigate the impact of secondary infections.
The report concludes that, while efforts have already been made to model antimicrobial resistance and prevention strategies, model updates and consistent outcomes have been hampered by gaps in scope, geographical coverage, drug-pathogen combinations, and viral-bacterial dynamics.
Those interested in this developing topic can read the full text here: The neglected model validation of antimicrobial resistance transmission models – a systematic review | Antimicrobial Resistance & Infection Control.
The European Vaccine Initiative, coordinator of the PrIMAVeRa project, applauds this continued step toward victory in the ongoing battle against antimicrobial-resistant pathogens, and looks forward to further PrIMAVeRa outputs.
This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and
innovation programme and EFPIA. www.imi.europa.eu
This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.
